A synergy of excellence: Novavax-Mabion partnership during unprecedented times amid the COVID-19 pandemic
Cooperation beetween Mabion i Novavax after signing the MCMA
The COVID-19 pandemic caused an unprecedented crisis that had to be quickly addressed by the development of effective vaccines. Novavax was among several companies that took up the gauntlet and managed to introduce a vaccine (Nuvaxovid) in less than two years since the beginning of the pandemic.
Starting in late 2021, Mabion supported Novavax in their endeavor by performing manufacturing and analytical services. High quality and timely performance enabled the extension of the cooperation to include more QC activities, such as those related to its updated XBB.1.5 strain vaccine.
Mabion as a reliable partner for outsourcing the manufacturing of biologic products became part of Novavax’s service providers network as well as their mission to develop effective and safe vaccines. Mabion proved that a dedicated team of talented, well-trained, and committed employees, together with their determination, openness, and great flexibility towards the Client, enable delivering services at the highest quality standards. In less than two years Novavax successfully registered its product with EMA and FDA.
